Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
May 04, 2016 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today that its Board of Directors has appointed Davis S. Caskey to...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Third Quarter of Fiscal Year 2016
February 09, 2016 16:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2015, the third quarter...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
November 09, 2015 16:37 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
October 21, 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of...
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
August 06, 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
December 16, 2014 08:38 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property...
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
December 03, 2014 09:55 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...
Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
September 09, 2014 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the...
Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
September 03, 2014 13:47 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
August 14, 2014 16:14 ET
|
Elite Pharmaceuticals, Inc.
Revenues Increase by 61%, Product Development on Schedule
Conference Call Scheduled for Monday, August 18th at 11:00 AM EDT
NORTHVALE, N.J., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Elite...